Table 5.

Effect of body fat percentage change on distant metastasis and survival by menopausal status in women with breast cancer

	Premenopausal (n = 86)			Postmenopausal (n = 45)
	B (± SE)	HR (95% CI)	p	B (± SE)	HR (95% CI)	p
Metastasis
Advanced disease (Stage III)	1.9 (± 0.6)	6.4 (1.83–22.64)	.004	2.5 (± 1.0)	11.7 (1.55–88.07)	.017
ER positive	1.7 (± 0.9)	5.5 (0.86–35.11)	.071	−0.3 (± 0.9)	0.8 (0.13–4.59)	.781
PR positive	−1.3 (± 0.8)	0.3 (0.06–1.22)	.088	0.3 (± 0.9)	1.4 (0.21–8.70)	.749
Age	−0.1 (± 0.1)	0.9 (0.83–0.99)	.029	0.1 (± 0.1)	1.0 (0.90–1.12)	.940
Regular exercise	−0.4 (± 1.1)	0.7 (0.08–6.00)	.739	0.1 (± 0.7)	1.1 (0.24–4.57)	.945
Body fat % change	0.1 (± 0.1)	1.1 (0.95–1.21)	.278	0.3 (± 0.1)	1.3 (1.02–1.72)	.035
Death
Advanced disease (Stage III)	3.2 (± 1.0)	24.7 (3.77–161.63)	.001	4.7 (± 1.9)	106.5 (2.78–4084.85)	.012
ER positive	2.1 (± 1.3)	8.6 (0.71–103.50)	.091	−0.9 (± 1.3)	0.4 (0.03–4.88)	.476
PR positive	−2.0 (± 1.1)	0.1 (0.02–1.14)	.067	−0.5 (± 1.4)	0.6 (0.04–10.19)	.749
Age	−0.1 (± 0.1)	0.9 (0.87–1.11)	.769	0.1 (± 0.1)	1.1 (0.92–1.29)	.298
Regular exercise	0.3 (± 1.2)	1.3(0.13–13.24)	.815	−1.1 (± 1.1)	0.3(0.04–2.75)	.312
Body fat % change	0.1 (± 0.1)	1.1(0.95–1.33)	.188	0.4 (± 0.2)	1.5(0.94–2.25)	.091

BMI body mass index, ER estrogen receptor, PR progesterone receptor, CI confidence interval